Loading…
ALLR
Allarity Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 016744500
$1.41+2.17%Price as of Aug 29, 18:43 UTC · updated once a day, after the close
Key metrics
- Market cap
- $22.43M
- P/E
- —
- Forward P/E
- —
- P/B
- 6.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.79
- ROE
- -157.09%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 0.51
- 52-week high
- $2.06
- 52-week low
- $0.77
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.08 | $1.17 | $330.60 | $246,960.00 | $8,715,000.00 | |
| P/S | — | 53.4x | — | — | — | — |
| P/B | 1.7x | 1.7x | 1.7x | — | — | 5.3x |
| EPS | -$0.78 | -$15.65 | -$6,156.00 | -$1,856,052.00 | -$3,519,600.00 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ABVCABVC Biopharma Inc | $0.83 | — | 2.1x | — | -69.86% | $22.12M |
| MRKRMarker Therapeutics, Inc. | $1.37 | — | 1.9x | — | -76.87% | $22.84M |
| RVPRetractable Technologies Inc | $0.73 | — | 0.3x | — | -4.51% | $21.85M |
| CNSYCerenome Inc | $3.05 |
About the company
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
- 7
- Tarpon Springs, United States
Company description provided by Yahoo Finance.